China-Exposed Global Stocks Are Bleeding the Most in 2016 Replay
(Bloomberg) -- Stocks hitched to the China growth wagon are stalling, with echoes of 2016's slowdown.
Companies that earn a large chunk of their revenues from the country have become market pariahs, thanks to the toxic mix of a trade war, worries over slowing global growth, and the bear market that's engulfing Asian equities.
Indexes tracking both U.S. and global stocks with significant exposure to China plunged about 4 percent each Wednesday, their biggest fall since 2016, according to Morgan Stanley and MSCI gauges. The U.S. measure is on track to post its worst month on record, even with a slight rebound on Thursday.
During yesterday's bounce, which sent the S&P 500 up 1.9 percent, the Morgan Stanley index still underperformed the benchmark to trade at its lowest price versus the main equity gauge in over a year.
“The trade war between U.S. and China is unlikely to be resolved quickly and there is growing evidence that it is having a negative effect on emerging market / European activity and confidence,” according to Emmanuel Cau, head of European equity strategy at Barclays Plc.
“In a sense, it feels like Goldilocks got eaten by the bears,” he wrote in a note Friday.
To contact the reporter on this story: Dani Burger in London at dburger7@bloomberg.net
To contact the editors responsible for this story: Samuel Potter at spotter33@bloomberg.net, Yakob Peterseil, Sid Verma
©2018 Bloomberg L.P.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.